Atopic Hand Eczema Research Study

Company: Leo Pharma, Inc.
Study: A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with placebo in subjects with moderate-to-severe atopic hand eczema who are candidates for systemic therapy (ADHAND)

Atopic Hand Eczema is a common condition that can cause hands to become red, swollen, and dry to the point of peeling or flaking. For many people, atopic hand eczema is a chronic condition that either keeps coming back or never fully goes away. And like many skin conditions, atopic hand eczema is not only uncomfortable but can take a toll on self-esteem, causing sufferers to feel embarrassed or self-conscious.

Right now, doctors at select centers in the US and Canada are conducting a new research study that may be able to help. The study is for an investigational medication for atopic hand eczema. If you are 18 or older and struggle with moderate or severe atopic hand eczema, you may qualify to participate.

If you join, you will receive all study-related care at no cost from a local physician, and you may also be reimbursed for your travel to attend study visits.

See If You Qualify

Please take the questionnaire below to see if you might qualify, get connected, and learn more.

Frequently Asked Questions

Register for trial participation

"*" indicates required fields

Select A Trial You Are Interested In*
Please select one or more trials that you are interested in participating in. Upon gathering further information, we will determine your eligibility.
This field is for validation purposes and should be left unchanged.

For more information, please contact:

The Derm Institute of West MI
1661 Crystal Springs Blvd. SE
Caledonia, MI 49316